Try the modernized beta website. Learn more about the modernization effort.

Key Record Dates Identifier: NCT03220477
Brief Title: Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

First Submitted : July 14, 2017
First Submitted that Met QC Criteria : July 14, 2017
First Posted : July 18, 2017

Last Update Submitted that Met QC Criteria : December 1, 2021
Last Update Posted : December 2, 2021